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Abstract 
A highly sensitive, selective and reproducible chromatographic method is 
described for determination of low-molecular mass unsaturated aliphatic aldehydes in 
human serum. The method combines fluorescent labeling using 4-(N,N-
Dimethylaminosulfonyl)-7-hydrazino-2,1,3-benzoxadiazole with peroxyoxalate-
chemiluminescence. The derivatives were separated on a reversed-phase column C8 
isocratically using a mixture of acetonitrile and 90 mM imidazole-HNO3 buffer (pH 
6.4, 1:1, % v/v). The calibration ranges were: 20-420 nM for methylglyoxal, 16-320 
nM for acrolein, 15-360 nM for crotonaldehyde and 20-320 nM for trans-2-hexenal. 
The detection limits were ranged from 4.4 to 6.5 nM (88-130 fmol/injection), the 
recovery results were within the range of 87.4-103.8% and intra and inter-day 
precision results were lower than 5.5%. The proposed validated method has been 
successfully applied to healthy, diabetic and rheumatic arthritis patients' sera with 
simple pretreatment method. In conclusion, this new method is suitable for routine 
analysis of large numbers of clinical samples for assessment of the oxidative stress 
state in patients.  
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Oxidative stress is a condition associated with the imbalance between 
production of reactive oxygen species (ROS) and the antioxidant defense system in 
vivo [1]. ROS initiates lipid peroxidation (LPO) process by their reaction with 
polyunsaturated fatty acids (PUFAs) in cellular membranes forming numerous 
aldehydic end products [2]. From these end products, the low-molecular mass 
unsaturated aliphatic aldehydes (LMMUAA) are the most cytotoxic one due to the 
presence of both alkene and aldehydic group. These reactive groups can react rapidly 
with DNA and protein leading to many pathological diseases such as atherosclerosis, 
diabetes mellitus (DM), rheumatic arthritis (RA), chronic renal failure, cancer and 
neurodegenerative diseases [1,3-8].  
To date, almost all the previous articles [10-22] highlighted on determination 
of LMMUAA individually in biological fluids. However, analysis of a broad spectrum 
of LMMUAA will provide a complete picture of the overall oxidation process to 
evaluate their role in the pathogenesis of these diseases. Therefore, a sensitive, 
selective and reproducible method for simultaneous determination of methylglyoxal 
(MG), acrolein (AC), crotonaldehyde (CR) and trans-2-hexenal (HE) in healthy and 
different patients' sera is developed.    
 However, direct determination of LMMUAA is difficult due to absence of 
intrinsic chromophores or fluorophores and chemical derivatization is required to 
convert them to a detectable and stable structures. Until now, several hydrazine based 
reagents such as 2,4-dinitrophenylhydrazine [9,10], dansylhydrazine [11], 2,4,6-
trichlorophenylhydrazine [12,23] were used for determination of aldehydes. Beside 
hydrazine reagents, several reagents containing diamine group were used for 
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determination of MG only such as 1,2-diamine-4,5-dimethoxybenzene [13,14], 1,2-
diamino-1,2-diphenylethane [15], 2,3-diamino-2,3-dimethylbutane [16], 4,5-dimethyl-
1,2-phenylenediamine [17], and 5,6-diamino-2,4-hydroxypyrimidine sulfate [18] 
Furthermore, other reagents such as o-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine 
hydrochloride [19], 1,3-cyclohexandione [20], 2-thiobarbituric acid [21], and 
fluorescein-5-thiosemicarbazide [22] were used for aldehyde derivatization.  
Although various reagents have been used so far but some methods lack of 
sufficient sensitivity [10-16,23], suffer from harsh conditions [13,14,20-22], or 
require expensive instrumentation which may be not available in all laboratories 
[17,19,20].  
To overcome these problems, 4-(N,N-dimethylaminosulfonyl)-7-hydrazino-
2,1,3-benzoxadiazole  (DBD-H), fluorogenic labeling reagent, was used in this study. 
DBD-H contains hydrazine group (-NH-NH2) which reacts specifically towards 
aldehydes and ketones, however its reaction with aldehydes is much faster and 
proceed to a greater degree of completion than its reaction with ketones [24]. Uzo et 
al [25] and Nakashima et al [26] reported the reaction of DBD-H with saturated 
aliphatic aldehydes at room temperature within 30 min. However, its reaction with 
ketones proceeds at 4 °C and take 4-5 hr [26,27]. Therefore, DBD-H can be 
considered as a selective FL labeling reagent for LMMUAA determination in 
biological fluid at room temperature within 30 min and without any interference from 
coexisting ketonic compounds. In addition, the resultant fluorescent derivatives have 
large quantum Φ values, and long excitation and emission wavelengths which avoid 
the interference derived from the bio-matrixes [28]. Beside all these advantages, to the 
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best of our knowledge, DBD-H wasn't used before for determination of LMMUAA 
which indicates the novelty of the method.   
Furthermore, in this study a combination of FL labeling using DBD-H with 
peroxyoxalate chemiluminescence (PO-CL) will afford higher sensitivity for 
determination of trace amount of LMMUAA in human serum. 
Therefore, the present study aimed to develop a PO-CL detection method for 
simultaneous determination of LMMUAA after labeling with DBD-H. The proposed 
method was optimized, validated and successfully applied to serum samples from 
healthy subjects, DM and RA patients and the measured biomarkers were compared to 
investigate their role in the pathogenesis of these diseases.   
 
2. Experimental 
2.1. Chemicals  
AC, 4-ethylbenzaldehyde used as an internal standard (IS), DBD-H, bis (2,3,5-
trichloro-6-((pentyloxy)carbonyl)phenyl)oxalate (CPPO), bis (2,4,6-trichlorophenyl) 
oxalate (TCPO) and imidazole were purchased from Tokyo Chemicals Industry 
(Tokyo, Japan). CR, trifluoroacetic acid (TFA), hydrogen peroxide, and bis (4-nitro-2-
(3,6,9-trioxadecyloxycarbonyl)phenyl)oxalate (TDPO) were purchased from Wako 
Pure Chemical Industries (Osaka, Japan). MG was purchased from Sigma–Aldrich 
(Milwaukee, WI, USA). HE was purchased from Nacali Tesque (Kyoto, Japan). 
Nitric acid, methanol and acetonitrile were obtained from Kanto Chemical Company 
(Tokyo). The water was purified by a Simpli Lab UV (Millipore, Bedford, MA, USA). 
All reagents used were of analytical grade. The stock solution of aldehydes and 
internal standard were prepared in methanol at a concentration of 5 mM and saved in 
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4 °C for one month. To obtain reproducible results, daily working solutions were 
prepared by diluting the stock solutions with methanol to obtain the required 
concentrations. Solutions of DBD-H and TFA were prepared in acetonitrile.                                
 
2.2. Apparatus 
The HPLC-PO-CL system consisted of two Shimadzu LC-20AD pumps 
(Kyoto, Japan), a Rheodyne (Cotati, CA, USA) 7125 injector with a 20-μL sample 
loop. The chromatographic separation was performed on a Cosmosil 5C8-MS (150 
mm×4.6 mm, I.D., 5µm) from Nacalai Tesque by an isocratic elution with a mixture 
of acetonitrile and 90 mM imidazole–HNO3 buffer (pH 6.4, 1:1, % v/v). CL signal 
was measured using a Shimadzu CLD-10A chemiluminescence detector using a 
mixture of 0.7 mM CPPO  and 15 mM hydrogen peroxide in acetonitrile as a post 
column CL reagent, and UNI-1 noise cleaner (Union, Gunma, Japan) which smoothes 
the baseline. The mobile phase and CL reagent were degassed by vacuum degassing 
with sonication and filtered through a 0.45-μm filter prior to use. The flow rates of the 
mobile phase and post column CL reagent were set at 0.7 and 0.8 mL/min, 
respectively.  
For the HPLC-FL system, a Shimadzu RF-20AXS fluorescence detector was 
used where the excitation and emission wavelengths were set at 445 and 553 nm, 
respectively. The HPLC systems were connected to an EZChrom Elite 
chromatography data acquisition system (Scientific software, Pleasanton, CA, USA). 
 
2.3. Fluorescence labeling procedure 
 6 
In a screw-capped vial, 100 µL of a mixture of aldehyde solution in methanol, 
100 µL of 10 mM DBD-H and 100 µL of 10% TFA were added. After vortex-mixing, 
the reaction mixture was left at room temperature for 30 min. An aliquot of 20 µL was 
injected into the HPLC system after filtration through a 0.45-µm cellulose acetate 
membrane filter. 
 
2.4. Sample collection 
Serum samples were obtained from 12 healthy volunteers (6 females, 6 males; 
age range, 48-62; mean age 55.2 ± 4.8) and from 12 DM patients (5 females, 7 males; 
age range, 39-69; mean age 52.3 ± 10.1) and from 12 RA patients (9 females, 3 males; 
age range, 43-84; mean age 65.1 ± 11.9) attending Sasebo Chuo Hospital. The 
collected serum samples were frozen at –80 °C prior to analysis. The present 
experiments were approved by the Ethics Committee of the School of Pharmaceutical 
Sciences, Nagasaki University, and performed in accordance with established 
guidelines. 
 
2.5. Pretreatment of serum sample 
To a 100 µL of serum sample, 20 µL of IS (10.8 ng/mL), 100 µL of 10 mM 
DBD-H, and 100 µL of 10% TFA were added in a 2.0-mL eppendorf tube. The 
mixture was vortex mixed and left at room temperature for 30 min then centrifuged at 
2200 x g for 20 min at 4° C.  A 20 µL of the clear supernatant was injected into the 




2.6. Data analysis                                                                                                              
             The data are presented as mean ± standard error (SE) for the number of 
experiments. The current study employed the decision tree method proposed by 
to determine if there is a difference in ]. Bartlett's test was used 29Kobayashi [
It  .(healthy, diabetic, and rheumatic subjects) groups 3 studied variance between the
was found that the k sampled populations have unequal variances and Steel's multiple 
comparison tests was used for subsequent data analysis. All the statistical tests were 
two-sided at a significant level of α= 0.01.                                                              .        
 
3. Results and discussion 
3.1. Optimization of fluorescence labelling conditions 
             In the present study, the target aldehydes were first labeled with DBD-H to 
form fluorescence hydrazone derivative as shown in Fig.1. In order to obtain higher 
reaction yields, labeling conditions including reagent concentrations, reaction 
temperature and time were optimized by using a standard mixture of the studied 
aldehydes (2 µM each). The effect of different concentrations of DBD-H (1-14 mM) 
and TFA (2-12%) on the fluorescence intensities of the labeled aldehdyes were tested. 
It was found that the maximum peak areas were obtained in the presence of 10 mM of 
DBD-H (Fig. S1a, supplementary data) and 10% of TFA (Fig. S1b, supplementary 
data), respectively. The reaction temperature and time were also investigated. The 
reaction proceeded at room temperature (25 ± 5) °C and the highest and stable peak 
areas were obtained after 20 min; so 30 min was selected as reaction time.                  . 
                             .                                                                                  .   
3.2. Optimization of chemiluminescence reaction variables  
 8 
Previously, it was reported that diaryloxalate esters with electron withdrawing 
groups are known to provide the highest quantum yield [30]. Therefore, the effects of 
CPPO, TDPO, and TCPO on CL intensity were tested using Sirius Luminometor 
(Berthold Technologies, Bad Wildbad, Germany). Among the tested diaryloxalate 
esters, CPPO gave the highest CL intensities (310) compared to TDPO (304) and 
TCPO (298) using AC as representative aldehyde. Therefore, CPPO was selected as 
the optimum diaryloxalate ester and its concentration was examined from 0.4 to 1.4 
mM using HPLC-PO-CL system and the optimum concentration was 0.8 mM by 
monitoring the signal-to-noise ratio (S/N) for aldehydes peaks (Fig. 2Sa, 
supplementary data). The concentration of hydrogen peroxide was examined from 5 
to 50 mM and 15 mM was selected as optimum concentration (Fig. 2Sb, 
supplementary data). Imidazole was identified as the best catalyst for PO-CL reaction 
and nitric acid is the best acid used in combination with imidazole to form buffer 
solutions as reported before [30,31]. The pH of the mobile phase has a great effect on 
CL intensities; therefore different buffer solutions from 5.8 to 7.2 were studied and 
the optimum pH was 6.4, as shown in Fig. S3a (supplementary data).  Finally, the 
flow rate of the CL reagent was varied from 0.2 to 1.5 mL/min, increase in signal 
intensities were observed by increasing the flow rate. However, flow rate above 0.8 
mL/min led to an increase in the noise; therefore 0.8 mL/min was thus selected as the 
optimum flow rate as shown in Fig. S3b (supplementary data).  A chromatogram of 
the studied LMMUAA after optimization of both FL labelling and PO-CL conditions 
was shown in Fig. 2. 
 
3.3. Method Validation 
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A standard mixture of the studied aldehydes with different concentrations was 
analyzed under the optimized reaction conditions. The calibration curves showed 
good linearity between concentration and peak area ratio over concentration range 
from 15 to 420 nM and the detection limits were in the range from 4.4 to 6.5 nM (88-
130 fmol/injection) at (S/N=3), as shown in Table 1 (supplementary data). On the 
other hand, the detection limits of the studied aldehydes obtained by FL detection 
were in the range from 43 to 46 nM. These results were 7-10 times less sensitive than 
PO-CL detection which indicated that the application of PO-CL for the detection of 
DBD-labelled aldehydes would improve the sensitivity. The higher sensitivity of the 
proposed HPLC-PO-CL method was brought by the significant reduction in baseline 
noise due to lack of external excitation source. 
 The sensitivity of the HPLC-PO-CL method was 4 and 10 times more 
sensitive compared with HPLC-UV [10,13], 14 times compared with CE-LIF [11], 4-
34 times compared with GC-MS [12,23], 12 times compared with MEKC [15], 20 
times compared with GC-FID [16], 13 and 76 times compared with HPLC-FL [14,19] 
and 34 times compared with LC-MS [20].  
The reproducibility of the proposed method was examined using three 
different concentrations of the studied aldehydes. The precision was expressed by 
relative standard deviation (RSD). It was found that RSD values for intra-day (n=5) 
and inter-day (n=5) precision were 1.0-3.2 and 1.2-3.8%, respectively as shown in 
Table 2 (supplementary data). It was confirmed that the proposed method have 
sufficient reproducibility.  
The proposed method showed high sensitivity and good reproducibility 
without requiring expensive instrumentation which may be not available in all 
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laboratories. In addition, the pretreatment method was simple, fast and doesn't 
requires further clean up methods to remove excess reagent. These advantages 
decreased the analysis time and made our proposed method more suitable for routine 
analysis of large numbers of clinical samples other than previous methods [14,20,21]. 
 
3.4. Determination of unsaturated aliphatic aldehydes in human serum 
The validation studies of biological fluid were carried out using pooled serum 
sample pre-analyzed for aldehyde contents before spiking with standard aldehydic 
solutions. Calibration curves showed good linearity between concentration and peak 
area ratio over concentration range from 16 to 420 nM and the detection limits were in 
the range from 4.9 to 6.9 nM (98-138 fmol/injection) at (S/N=3), as shown in Table 3 
(supplementary data).   
To evaluate intra and inter-day precision, five replicates of three sets of serum 
samples spiked with three different concentration levels of standard aldehyde 
solutions were performed. It was found that RSD values for intra-day (n=5) and inter-
day (n=5) precision were 1.4-4.0% and 2.7-5.4%, respectively. The recovery of the 
proposed method was determined by using serum samples spiked with standard 
mixture of aldehyde solution at three concentrations before derivatization. Recoveries 
were expressed as [(found amount/ spiked amount) x100%] and found to be higher 
than 87%, which is higher than previous methods [10,12,19,25] and the results are 
listed in Table 1. 
 
3.5. Data analysis of aldehydes in health, DM and RA sera 
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The proposed method was applied for determination of the studied aldehydes 
in human sera. Fig. 3 shows typical chromatograms of spiked serum sample and sera 
samples from healthy, DM and RA patients determined by the proposed method. The 
peaks of the studied LMMUAA were detected clearly in the chromatogram without 
any interference from other biological components. However, the peaks appeared in 
the chromatograms before 5 min were attributed to shorter chain aliphatic aldehydes 
which may be produced in vivo either from LPO or from other biological process. 
 The concentration of the studied aldehydes were compared between healthy 
subjects, DM and RA patients using Steel's multiple test [29,32] the statistical tests 
were two-sided at a significant level of α=0.01. The results were summarized in Table 
2 and healthy subjects' results were in good agreement with other previous reports 
[5,9,12,21]. 
In DM patients, serum MG and AC level were found to be significantly higher 
than those in controls (p<0.01). The simultaneous elevated level of both MG and AC 
can be used as a distinguishable marker to measure the severity of oxidative stress in 
DM and its contribution to many diabetic complications. The endogenous formation 
of MG may be either from autoxidation of sugars and glycation reaction [3], LPO 
process [13] or from lipid and protein catabolism [33]. These processes are elevated in 
DM patients and consequently MG level is elevated too. In addition, Meszaros et al 
[34] and Garpenstrand et al [35] reported the elevated activity of sensitive 
semicarbazide aminoxidase (SSAO) enzyme, which catalyzes the deamination of 
endogenous primary amines to MG, in DM patients than healthy human. As a result, it 
is considered that monitoring of MG biogenesis in diabetic patients might help to 
assess the risk of progression of diabetic complications. In addition, the elevated level 
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of AC in DM patients may be due to the elevated glucose level which consequently 
stimulates the production of AC from PUFAs in LPO process [36]. 
For the first time, we found a significantly elevated level of AC in RA patients 
than those in controls (p<0.01). This elevated level may be due to the elevated level of 
oxidative stress in RA patients [37]. Beside oxidative stress, Stevens et al [38] found 
that the oxidative deamination of polyamine compounds is another significant source 
of AC in vivo. These polyamine compounds were detected in high concentrations in 
RA patients' urine samples as reported by Furumitsu et al [39]. The pathophysiology 
of DM and RA diseases is mostly related to oxidative stress, so MG and AC can be 
used as oxidative stress biomarkers. However, CR and HE concentrations were found 
to be insignificantly higher in DM and RA sera than those in controls and they can't 
be considered as oxidative stress biomarkers for either DM or RA.  
 
4. Conclusion 
In this study, the feasibility of PO-CL detection method for simultaneous 
determination of LMMUAA after labeling with DBD-H was demonstrated. The 
proposed method was successfully applied to determine LMMUAA in healthy, DM 
and RA human sera without any interference from the biological components after 
simple pretreatment method. For the first time, we found a significant elevation in AC 
concentration in serum of RA patients compared to healthy humans. In addition, a 
significant elevation of both MG and AC were found in DM patients compared to 
healthy humans that confirms suitability of using MG and AC as biomarkers for DM 
and RA. Since the proposed method is sensitive, selective, reproducible and doesn't 
 13 
require expensive instrumentation the method should be suitable for routine analysis 
of large numbers of clinical samples for the evaluation of oxidative stress process. 
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Fig. 1. Reaction scheme of aldehyde derivatization with DBD-H and the structure of  
the studied aldehydes . 
                                                                                                      
Fig. 2. Representative chromatograms of (a) reagent blank, (b) standard solution of a 
mixture of the studied aldehydes (120 nM each) with peroxyoxalate 
chemiluminescence detection, and (c) standard solution of a mixture of the studied 
aldehydes (120 nM each) with fluorescence detection, peaks: 1-MG, 2-AC, 3-CR, and  
4-HE.     
                                                                                                                             
Fig. 3. Chromatograms of (a) human serum spiked with a mixture of the studied 
aldehydes (200 nM each), (b) healthy human serum, (c) DM patient serum, and (d)      





Fig. 1. Reaction scheme of aldehyde derivatization with DBD-H and the 
structure of the studied aldehydes   
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Fig. 2. Representative chromatograms of (a) reagent blank, (b) standard 
solution of a mixture of the studied aldehydes (120 nM each) with 
peroxyoxalate chemiluminescence detection, and (c) standard solution of a 
mixture of the studied aldehydes (120 nM each) with fluorescence detection,  
peaks: 1-MG, 2-AC, 3-CR, and 4-HE 
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Fig. 3. Chromatograms of (a) human serum spiked with a mixture of the 
studied aldehydes (200 nM each), (b) healthy human serum, (c) DM patient 
 serum, and (d) RA patient serum; peaks 1-4 as in Fig.2 
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Table 1 Recovery and precision of the proposed method for aldehydes in serum 
samples                    
 
Aldehyde Spiked amount 
(nM) 
Intra-day (n=5) Inter-day (n=5) 
Found ± SD 
  
RSD% Recovery% Found ± SD RSD% Recovery% 
MG 20 18.2±0.73 4.0 91.0 17.5±0.78 4.5 87.5 
 200 195.4±3.3 1.7 97.7 197.2±7.3 3.7 98.6 
 420 389.6±8.57 2.2 92.8 402±15.7 3.9 95.7 
AC 16 14.5±0.48 3.3 90.6 14.2±0.77 5.4 88.8 
 120 121.4±3.3 2.7 101.1 123.5±4.4 3.6 102.9 
 320 305±10.1 3.3 95.3 300.4±10.5 3.5 93.9 
CR 16 14.9±0.3 1.9 93.1 14.5±0.5 3.4 90.6 
 120 124.6±1.7 1.4 103.8 121.3±3.3 2.7 101.1 
 360 362.8±6.2 1.7 100.8 360.1±10.4 2.9 100 
HE 20 19.3±0.54 2.8 96.5 18.8±0.7 3.7 94.0 
 120 109.1±1.6 1.5 90.9 104.9±4.1 3.9 87.4 
 320 286.4±9.5 3.3 89.5 297.6±13.1 4.4 93.0 
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Table 2 Aldehydes concentration in healthy, diabetic and rheumatic arthritis patients 
sera (n=12 each) 
 
  Aldehyde data 
Range (nM) aSE ±Mean  b95% CI c,*Statistical test  
MG Healthy 141.4-152.6 146.5± 1.0 144.6-148.4 ----- 
 DM 281.7-314.8 299.1 ± 2.8 293.7-304.5 Healthy < DM 
 RA 140.1-150.5 145.3 ± 1.1 143.1-147.5 ----- 
AC Healthy 38.4-57.0 42.2 ± 1.6 39.1-45.3 ----- 
 DM 61.0-75.6 68.7 ± 1.4 65.9-71.5 Healthy < DM 
 RA 73.1-81.5 76.3 ± 0.7 74.9-77.7 Healthy < RA 
CR Healthy 57.2-64.9 61.3 ± 0.8 59.8-62.8 ----- 
 DM 59.8-68.4 63.5 ± 0.3 61.7-65.3 ----- 
 RA 58.6-64.1 60.9 ± 0.4 60.1-61.7 ----- 
HE Healthy 55.1-66.3 59.5 ± 1.2 57.2-61.8 ----- 
 DM 54.4-69.9 59.2 ± 1.2 56.9-61.5 ----- 
 RA 58.5-70.7 61.7 ± 1.0 59.8-63.6 ----- 
 Standard error a 
Confidence interval  b 
Steel's test c 




Fig. S1. Effects of (a) DBD-H and (b) TFA concentrations on relative peak areas of a 



























Fig. S2. Effects of (a) CPPO and (b) hydrogen peroxide concentrations on signal-to-
noise ratio of a mixture of the studied aldehydes (120 nM each), the data represent 
































Fig. S3. Effects of (a) pH and (b) flow rate on signal-to-noise ratio of a mixture of the 

























Table S1 Retention times, calibration curves and detection limits for standard aldehyde solutions 
 
.Y= peak area ratio; X= sample concentration (nM) a 































, nM b LOD
(fmol/injection)  
2r , n=3a Calibration curve Range, nM Compound 
6.5 (131) 0.9988 Y= 0.034 + 0.011 X 20-420 MG 
4.9 (98) 0.9992 Y= 0.010 + 0.016 X 16-320 AC 
4.4 (88) 0.9992 Y= 0.010 + 0.011 X 15-360 CR 




Table S2 Precision results for determination of standard aldehydic solution using the 
proposed method  
 
Inter-day assay (n=5) 
RSD % 




3.8 2.5 20 
MG 1.9 1.0 200 
1.2 1.0 420 
3.2 1.4 16 
AC 3.4 3.2 200 
1.7 1.6 320 
3.1 2.6 15 
CR 2.5 2.4 200 
2.0 1.9 360 
2.7 1.7 20 
HE 2.6 1.6 200 
1.5 1.4 320 
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Y= peak area ratio; X= sample concentration (nM). a 








, nM b LOD
(fmol/injection)  
2r , n=3a Calibration curve Range, nM Compound 
(138) 6.9 0.9986 Y= 0.012 + 0.010 X 20-420 MG 
5.0 (100) 0.9990 Y= 0.016 + 0.016 X 16-320 AC 
4.9 (98) 0.9990 Y= 0.015 + 0.011 X 16-360 CR 
 6.0 (120) 0.9986 Y= 0.012 + 0.012 X 20-320 HE 
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